Advertisement
Research ArticleNephrology Free access | 10.1172/JCI70143
1Institutes of Molecular Medicine and Experimental Immunology, Rheinische Friedrich-Wilhelms University, Bonn, Germany. 2Paris Cardiovascular Research Centre, INSERM, and Université Paris Descartes, Sorbonne Paris Cité, Paris, France. 3Department of Anesthesiology and Intensive Care Medicine, Rheinische Friedrich-Wilhelms University, Bonn, Germany. 4Institute of Molecular Immunology, Technische Universität, Munich, Germany. 5III Medizinische Klinik, Universitätsklinikum Hamburg-Eppendorf, Germany.
Address correspondence to: Katharina Hochheiser, Institutes of Molecular Medicine and Experimental Immunology (IMMEI), Friedrich-Wilhelms-Universität, 53105 Bonn, Germany. Phone: 49.228.287.11033; Fax: 49.228.287.11052; E-mail: khochhei@uni-bonn.de. Or to: Christian Kurts, Institutes of Molecular Medicine and Experimental Immunology (IMMEI), Friedrich-Wilhelms-Universität, 53105 Bonn, Germany. Phone: 49.228.287.11050; Fax: 49.228.287.11052; E-mail: ckurts@web.de.
Find articles by Hochheiser, K. in: JCI | PubMed | Google Scholar
1Institutes of Molecular Medicine and Experimental Immunology, Rheinische Friedrich-Wilhelms University, Bonn, Germany. 2Paris Cardiovascular Research Centre, INSERM, and Université Paris Descartes, Sorbonne Paris Cité, Paris, France. 3Department of Anesthesiology and Intensive Care Medicine, Rheinische Friedrich-Wilhelms University, Bonn, Germany. 4Institute of Molecular Immunology, Technische Universität, Munich, Germany. 5III Medizinische Klinik, Universitätsklinikum Hamburg-Eppendorf, Germany.
Address correspondence to: Katharina Hochheiser, Institutes of Molecular Medicine and Experimental Immunology (IMMEI), Friedrich-Wilhelms-Universität, 53105 Bonn, Germany. Phone: 49.228.287.11033; Fax: 49.228.287.11052; E-mail: khochhei@uni-bonn.de. Or to: Christian Kurts, Institutes of Molecular Medicine and Experimental Immunology (IMMEI), Friedrich-Wilhelms-Universität, 53105 Bonn, Germany. Phone: 49.228.287.11050; Fax: 49.228.287.11052; E-mail: ckurts@web.de.
Find articles by Heuser, C. in: JCI | PubMed | Google Scholar
1Institutes of Molecular Medicine and Experimental Immunology, Rheinische Friedrich-Wilhelms University, Bonn, Germany. 2Paris Cardiovascular Research Centre, INSERM, and Université Paris Descartes, Sorbonne Paris Cité, Paris, France. 3Department of Anesthesiology and Intensive Care Medicine, Rheinische Friedrich-Wilhelms University, Bonn, Germany. 4Institute of Molecular Immunology, Technische Universität, Munich, Germany. 5III Medizinische Klinik, Universitätsklinikum Hamburg-Eppendorf, Germany.
Address correspondence to: Katharina Hochheiser, Institutes of Molecular Medicine and Experimental Immunology (IMMEI), Friedrich-Wilhelms-Universität, 53105 Bonn, Germany. Phone: 49.228.287.11033; Fax: 49.228.287.11052; E-mail: khochhei@uni-bonn.de. Or to: Christian Kurts, Institutes of Molecular Medicine and Experimental Immunology (IMMEI), Friedrich-Wilhelms-Universität, 53105 Bonn, Germany. Phone: 49.228.287.11050; Fax: 49.228.287.11052; E-mail: ckurts@web.de.
Find articles by Krause, T. in: JCI | PubMed | Google Scholar
1Institutes of Molecular Medicine and Experimental Immunology, Rheinische Friedrich-Wilhelms University, Bonn, Germany. 2Paris Cardiovascular Research Centre, INSERM, and Université Paris Descartes, Sorbonne Paris Cité, Paris, France. 3Department of Anesthesiology and Intensive Care Medicine, Rheinische Friedrich-Wilhelms University, Bonn, Germany. 4Institute of Molecular Immunology, Technische Universität, Munich, Germany. 5III Medizinische Klinik, Universitätsklinikum Hamburg-Eppendorf, Germany.
Address correspondence to: Katharina Hochheiser, Institutes of Molecular Medicine and Experimental Immunology (IMMEI), Friedrich-Wilhelms-Universität, 53105 Bonn, Germany. Phone: 49.228.287.11033; Fax: 49.228.287.11052; E-mail: khochhei@uni-bonn.de. Or to: Christian Kurts, Institutes of Molecular Medicine and Experimental Immunology (IMMEI), Friedrich-Wilhelms-Universität, 53105 Bonn, Germany. Phone: 49.228.287.11050; Fax: 49.228.287.11052; E-mail: ckurts@web.de.
Find articles by Teteris, S. in: JCI | PubMed | Google Scholar
1Institutes of Molecular Medicine and Experimental Immunology, Rheinische Friedrich-Wilhelms University, Bonn, Germany. 2Paris Cardiovascular Research Centre, INSERM, and Université Paris Descartes, Sorbonne Paris Cité, Paris, France. 3Department of Anesthesiology and Intensive Care Medicine, Rheinische Friedrich-Wilhelms University, Bonn, Germany. 4Institute of Molecular Immunology, Technische Universität, Munich, Germany. 5III Medizinische Klinik, Universitätsklinikum Hamburg-Eppendorf, Germany.
Address correspondence to: Katharina Hochheiser, Institutes of Molecular Medicine and Experimental Immunology (IMMEI), Friedrich-Wilhelms-Universität, 53105 Bonn, Germany. Phone: 49.228.287.11033; Fax: 49.228.287.11052; E-mail: khochhei@uni-bonn.de. Or to: Christian Kurts, Institutes of Molecular Medicine and Experimental Immunology (IMMEI), Friedrich-Wilhelms-Universität, 53105 Bonn, Germany. Phone: 49.228.287.11050; Fax: 49.228.287.11052; E-mail: ckurts@web.de.
Find articles by Ilias, A. in: JCI | PubMed | Google Scholar
1Institutes of Molecular Medicine and Experimental Immunology, Rheinische Friedrich-Wilhelms University, Bonn, Germany. 2Paris Cardiovascular Research Centre, INSERM, and Université Paris Descartes, Sorbonne Paris Cité, Paris, France. 3Department of Anesthesiology and Intensive Care Medicine, Rheinische Friedrich-Wilhelms University, Bonn, Germany. 4Institute of Molecular Immunology, Technische Universität, Munich, Germany. 5III Medizinische Klinik, Universitätsklinikum Hamburg-Eppendorf, Germany.
Address correspondence to: Katharina Hochheiser, Institutes of Molecular Medicine and Experimental Immunology (IMMEI), Friedrich-Wilhelms-Universität, 53105 Bonn, Germany. Phone: 49.228.287.11033; Fax: 49.228.287.11052; E-mail: khochhei@uni-bonn.de. Or to: Christian Kurts, Institutes of Molecular Medicine and Experimental Immunology (IMMEI), Friedrich-Wilhelms-Universität, 53105 Bonn, Germany. Phone: 49.228.287.11050; Fax: 49.228.287.11052; E-mail: ckurts@web.de.
Find articles by Weisheit, C. in: JCI | PubMed | Google Scholar
1Institutes of Molecular Medicine and Experimental Immunology, Rheinische Friedrich-Wilhelms University, Bonn, Germany. 2Paris Cardiovascular Research Centre, INSERM, and Université Paris Descartes, Sorbonne Paris Cité, Paris, France. 3Department of Anesthesiology and Intensive Care Medicine, Rheinische Friedrich-Wilhelms University, Bonn, Germany. 4Institute of Molecular Immunology, Technische Universität, Munich, Germany. 5III Medizinische Klinik, Universitätsklinikum Hamburg-Eppendorf, Germany.
Address correspondence to: Katharina Hochheiser, Institutes of Molecular Medicine and Experimental Immunology (IMMEI), Friedrich-Wilhelms-Universität, 53105 Bonn, Germany. Phone: 49.228.287.11033; Fax: 49.228.287.11052; E-mail: khochhei@uni-bonn.de. Or to: Christian Kurts, Institutes of Molecular Medicine and Experimental Immunology (IMMEI), Friedrich-Wilhelms-Universität, 53105 Bonn, Germany. Phone: 49.228.287.11050; Fax: 49.228.287.11052; E-mail: ckurts@web.de.
Find articles by Hoss, F. in: JCI | PubMed | Google Scholar
1Institutes of Molecular Medicine and Experimental Immunology, Rheinische Friedrich-Wilhelms University, Bonn, Germany. 2Paris Cardiovascular Research Centre, INSERM, and Université Paris Descartes, Sorbonne Paris Cité, Paris, France. 3Department of Anesthesiology and Intensive Care Medicine, Rheinische Friedrich-Wilhelms University, Bonn, Germany. 4Institute of Molecular Immunology, Technische Universität, Munich, Germany. 5III Medizinische Klinik, Universitätsklinikum Hamburg-Eppendorf, Germany.
Address correspondence to: Katharina Hochheiser, Institutes of Molecular Medicine and Experimental Immunology (IMMEI), Friedrich-Wilhelms-Universität, 53105 Bonn, Germany. Phone: 49.228.287.11033; Fax: 49.228.287.11052; E-mail: khochhei@uni-bonn.de. Or to: Christian Kurts, Institutes of Molecular Medicine and Experimental Immunology (IMMEI), Friedrich-Wilhelms-Universität, 53105 Bonn, Germany. Phone: 49.228.287.11050; Fax: 49.228.287.11052; E-mail: ckurts@web.de.
Find articles by Tittel, A. in: JCI | PubMed | Google Scholar
1Institutes of Molecular Medicine and Experimental Immunology, Rheinische Friedrich-Wilhelms University, Bonn, Germany. 2Paris Cardiovascular Research Centre, INSERM, and Université Paris Descartes, Sorbonne Paris Cité, Paris, France. 3Department of Anesthesiology and Intensive Care Medicine, Rheinische Friedrich-Wilhelms University, Bonn, Germany. 4Institute of Molecular Immunology, Technische Universität, Munich, Germany. 5III Medizinische Klinik, Universitätsklinikum Hamburg-Eppendorf, Germany.
Address correspondence to: Katharina Hochheiser, Institutes of Molecular Medicine and Experimental Immunology (IMMEI), Friedrich-Wilhelms-Universität, 53105 Bonn, Germany. Phone: 49.228.287.11033; Fax: 49.228.287.11052; E-mail: khochhei@uni-bonn.de. Or to: Christian Kurts, Institutes of Molecular Medicine and Experimental Immunology (IMMEI), Friedrich-Wilhelms-Universität, 53105 Bonn, Germany. Phone: 49.228.287.11050; Fax: 49.228.287.11052; E-mail: ckurts@web.de.
Find articles by Knolle, P. in: JCI | PubMed | Google Scholar
1Institutes of Molecular Medicine and Experimental Immunology, Rheinische Friedrich-Wilhelms University, Bonn, Germany. 2Paris Cardiovascular Research Centre, INSERM, and Université Paris Descartes, Sorbonne Paris Cité, Paris, France. 3Department of Anesthesiology and Intensive Care Medicine, Rheinische Friedrich-Wilhelms University, Bonn, Germany. 4Institute of Molecular Immunology, Technische Universität, Munich, Germany. 5III Medizinische Klinik, Universitätsklinikum Hamburg-Eppendorf, Germany.
Address correspondence to: Katharina Hochheiser, Institutes of Molecular Medicine and Experimental Immunology (IMMEI), Friedrich-Wilhelms-Universität, 53105 Bonn, Germany. Phone: 49.228.287.11033; Fax: 49.228.287.11052; E-mail: khochhei@uni-bonn.de. Or to: Christian Kurts, Institutes of Molecular Medicine and Experimental Immunology (IMMEI), Friedrich-Wilhelms-Universität, 53105 Bonn, Germany. Phone: 49.228.287.11050; Fax: 49.228.287.11052; E-mail: ckurts@web.de.
Find articles by Panzer, U. in: JCI | PubMed | Google Scholar
1Institutes of Molecular Medicine and Experimental Immunology, Rheinische Friedrich-Wilhelms University, Bonn, Germany. 2Paris Cardiovascular Research Centre, INSERM, and Université Paris Descartes, Sorbonne Paris Cité, Paris, France. 3Department of Anesthesiology and Intensive Care Medicine, Rheinische Friedrich-Wilhelms University, Bonn, Germany. 4Institute of Molecular Immunology, Technische Universität, Munich, Germany. 5III Medizinische Klinik, Universitätsklinikum Hamburg-Eppendorf, Germany.
Address correspondence to: Katharina Hochheiser, Institutes of Molecular Medicine and Experimental Immunology (IMMEI), Friedrich-Wilhelms-Universität, 53105 Bonn, Germany. Phone: 49.228.287.11033; Fax: 49.228.287.11052; E-mail: khochhei@uni-bonn.de. Or to: Christian Kurts, Institutes of Molecular Medicine and Experimental Immunology (IMMEI), Friedrich-Wilhelms-Universität, 53105 Bonn, Germany. Phone: 49.228.287.11050; Fax: 49.228.287.11052; E-mail: ckurts@web.de.
Find articles by Engel, D. in: JCI | PubMed | Google Scholar
1Institutes of Molecular Medicine and Experimental Immunology, Rheinische Friedrich-Wilhelms University, Bonn, Germany. 2Paris Cardiovascular Research Centre, INSERM, and Université Paris Descartes, Sorbonne Paris Cité, Paris, France. 3Department of Anesthesiology and Intensive Care Medicine, Rheinische Friedrich-Wilhelms University, Bonn, Germany. 4Institute of Molecular Immunology, Technische Universität, Munich, Germany. 5III Medizinische Klinik, Universitätsklinikum Hamburg-Eppendorf, Germany.
Address correspondence to: Katharina Hochheiser, Institutes of Molecular Medicine and Experimental Immunology (IMMEI), Friedrich-Wilhelms-Universität, 53105 Bonn, Germany. Phone: 49.228.287.11033; Fax: 49.228.287.11052; E-mail: khochhei@uni-bonn.de. Or to: Christian Kurts, Institutes of Molecular Medicine and Experimental Immunology (IMMEI), Friedrich-Wilhelms-Universität, 53105 Bonn, Germany. Phone: 49.228.287.11050; Fax: 49.228.287.11052; E-mail: ckurts@web.de.
Find articles by Tharaux, P. in: JCI | PubMed | Google Scholar
1Institutes of Molecular Medicine and Experimental Immunology, Rheinische Friedrich-Wilhelms University, Bonn, Germany. 2Paris Cardiovascular Research Centre, INSERM, and Université Paris Descartes, Sorbonne Paris Cité, Paris, France. 3Department of Anesthesiology and Intensive Care Medicine, Rheinische Friedrich-Wilhelms University, Bonn, Germany. 4Institute of Molecular Immunology, Technische Universität, Munich, Germany. 5III Medizinische Klinik, Universitätsklinikum Hamburg-Eppendorf, Germany.
Address correspondence to: Katharina Hochheiser, Institutes of Molecular Medicine and Experimental Immunology (IMMEI), Friedrich-Wilhelms-Universität, 53105 Bonn, Germany. Phone: 49.228.287.11033; Fax: 49.228.287.11052; E-mail: khochhei@uni-bonn.de. Or to: Christian Kurts, Institutes of Molecular Medicine and Experimental Immunology (IMMEI), Friedrich-Wilhelms-Universität, 53105 Bonn, Germany. Phone: 49.228.287.11050; Fax: 49.228.287.11052; E-mail: ckurts@web.de.
Find articles by Kurts, C. in: JCI | PubMed | Google Scholar
Published September 3, 2013 - More info
DCs and macrophages both express the chemokine receptor CX3CR1. Here we demonstrate that its ligand, CX3CL1, is highly expressed in the murine kidney and intestine. CX3CR1 deficiency markedly reduced DC numbers in the healthy and inflamed kidney cortex, and to a lesser degree in the kidney medulla and intestine, but not in other organs. CX3CR1 also promoted influx of DC precursors in crescentic glomerulonephritis, a DC-dependent aggressive type of nephritis. Disease severity was strongly attenuated in CX3CR1-deficient mice. Primarily CX3CR1-dependent DCs in the kidney cortex processed antigen for the intrarenal stimulation of T helper cells, a function important for glomerulonephritis progression. In contrast, medullary DCs played a specialized role in inducing innate immunity against bacterial pyelonephritis by recruiting neutrophils through rapid chemokine production. CX3CR1 deficiency had little effect on the immune defense against pyelonephritis, as medullary DCs were less CX3CR1 dependent than cortical DCs and because recruited neutrophils produced chemokines to compensate for the DC paucity. These findings demonstrate that cortical and medullary DCs play specialized roles in their respective kidney compartments. We identify CX3CR1 as a potential therapeutic target in glomerulonephritis that may involve fewer adverse side effects, such as impaired anti-infectious defense or compromised DC functions in other organs.
DCs exist in virtually all organs. They gather antigens and activate T cells after migrating into the draining lymph nodes. Additionally, tissue-resident DCs modulate local immune responses by regulating infiltrating effector cells or memory T cells (1–4). Tissue macrophages (MPs) differ from DCs by a higher capacity to endocytose and degrade antigen and to clear pathogens and apoptotic cells and by a lower ability to activate T cells (5). The classification of APCs as DCs or MPs is still controversial. The demarcation between MP and DC functions is not absolute, and cells with combined functionality in varying degrees exist (5). We recently demonstrated that kidney cells expressing CD11c and MHC-II possessed DC, but not MP, functionality (6). A recent transcriptome analysis of CD11c+ kidney cells supported this classification (7).
In the healthy kidney, DCs form an extensive network in the tubulointerstitium (8) that maintains tissue homeostasis and serves sentinel functions against various forms of injury (9, 10). They play a sentinel role in pyelonephritis (PN), the most common renal infection, in which uropathogenic E. coli ascend from the bladder through the tubular system into the kidney (4). In nephrotoxic nephritis (NTN), a murine model of human crescentic glomerulonephritis (GN) (11), kidney DCs initially performed an antiinflammatory function by attracting regulatory NKT cells (3, 12) but matured when inflammation became chronic (13). Then, they produced chemokines and cytokines that attracted and stimulated Th1 and Th17 cells, resulting in a mononuclear tubulointerstitial infiltrate that drove disease progression through an intrarenal delayed-type hypersensitivity (DTH) response (2, 14).
Chemokines play important roles in the tissue recruitment of leukocytes, both in homeostasis and inflammation. Distinct chemokine receptors have been linked with specific immune cells, the type of immune responses, and immune cell recruitment into particular organs. Thus, CCR9 is associated with immune cells in the intestine (15), CCR4 is associated with those in the skin and lung (16, 17), and CCR6 regulates the entry of Th17 cells and Tregs into the brain (18, 19). A specific receptor for the kidney has not yet been identified.
The chemokine receptor CX3CR1, also known as the fractalkine receptor, is expressed by monocytes, DCs, and MPs and on some memory T cells. CX3CR1 reporter mice, in which GFP expression is driven by the CX3CR1 promoter (20), have greatly facilitated analysis of these cells. However, mice lacking this receptor showed few abnormalities in the steady state, such as a reduced glucose tolerance due to CX3CR1 expression on pancreatic islet β cells (21) or lower MP numbers in the intestinal lamina propria (22). Intestinal DCs required CX3CR1 to sample antigen from the intestinal lumen (23). Little is known about the role of CX3CR1 in tissue DC homeostasis, especially in the kidney.
CX3CR1 has one ligand, CX3CL1, which is expressed by various tissue cells. A recent study using CX3CL1 reporter mice demonstrated remarkably strong expression of CX3CL1 in kidney glomerular and tubular cells (24). That study focused on intestinal DCs and therefore addressed neither the exact identity of CX3CL1+ kidney cells, nor functional implications. In the human system, CX3CL1 has been detected on tubular epithelial cells, especially under inflammatory conditions, like acute allograft rejection and GN (25). Concomitantly, an infiltration of CX3CR1+ monocytes and T cells into inflamed kidneys was observed in patients (26, 27).
Preclinical studies in disease models showed both beneficial and adverse effects of CX3CR1 in a context-dependent manner. Thus, CX3CR1 aggravated heart transplant rejection (28) and arteriosclerosis by recruiting monocytes and promoting their survival (29, 30). Conversely, CX3CR1 also enhanced monocyte survival in liver injury, but this attenuated hepatitis (31). Other protective roles of CX3CR1 include preventing subretinal accumulation of microglia in degenerative macular eye disease (32) and monocyte recruitment to the spleen in listeriosis (33). In kidney ischemia/reperfusion and hypertensive kidney fibrosis, CX3CR1 contributed to monocyte recruitment (34) and aggravated fibrosis (35, 36). Conflicting studies exist on the role of CX3CR1 in GN. While antibody blockade of CX3CR1 reduced monocyte and CD8+ T cell infiltration and ameliorated disease in rats (37), immune complex GN in CD1 mice was unaltered in CX3CR1-deficient mice (28). The role of CX3CR1 in NTN is presently unclear.
The kidney can be macroscopically divided into 2 compartments, the cortex and the medulla, which harbor different parts of the nephrons. The glomeruli and the proximal tubuli are found in the cortex, and the descending loop of Henle enters the medulla, returns to the cortex, and continues as the distal tubule, which enters the collecting tubules that again descend into the medulla. DCs are located in both compartments, but due to differential blood supply and osmotic concentrations they encounter highly differential environmental conditions. There is no information about functional differences between cortical and medullary DCs.
Here, we hypothesized that cortical DCs might be critical in GN, as the glomeruli are located in the cortex, whereas medullary DCs might be more important in PN, because the ascending bacteria first pass through the medulla. Our present findings confirm this hypothesis and demonstrate that CX3CR1 preferentially affects cortical DCs, identifying new therapeutic opportunities in GN.
Dependence of kidney DCs and MPs on CX3CR1 in healthy mice. CX3CR1 is abundantly expressed on most kidney APCs, whereas other immune cells constituted only minor fractions among CX3CR1+ kidney cells (ref. 8 and Supplemental Figure 1, A–C; supplemental material available online with this article; doi: 10.1172/JCI70143DS1). The functional role of CX3CR1 in kidney APCs is unclear. When we compared kidney sections of CX3CR1GFP/+ mice (expressing a GFP reporter in CX3CR1+ cells) and of CX3CR1GFP/GFP mice (expressing the GFP reporter and deficient for CX3CR1) by fluorescence microscopy, an obvious reduction of GFP+ cells in the absence of CX3CR1 was noted (Figure 1A). Analysis of kidney single cell suspensions by flow cytometry (gating strategy shown in Supplemental Figure 1D) revealed that exclusively the CX3CR1+ APCs expressing CD11c, which have been shown to possess DC functionality (6), were reduced by 75% in CX3CR1GFP/GFP mice, whereas CD11c– MPs were slightly, albeit not statistically significantly, enhanced (Figure 1B). Total DC and MP numbers did not differ between WT and CX3CR1GFP/+ mice (Supplemental Figure 2A), indicating that the latter could serve as CX3CR1-competent controls.
CX3CR1 specifically regulates the abundance of DCs in the kidney. (A) Representative kidney sections of CX3CR1GFP/+ reporter mice and CX3CR1GFP/GFP-deficient mice (original magnification, ×200). Arrows point to GFP+ cells. (B) CD11c versus MHC-II staining of CD45+GFP+ cells from CX3CR1GFP/+ reporter mice (left) and quantification of DCs (MHC-II+CD11c+) and MPs (MHC-II+CD11c–) (right) in CX3CR1GFP/+ (GFP/+) and CX3CR1GFP/GFP mice (GFP/GFP). Results of 5 individual experiments were combined. (C) Absolute numbers of GFP+ DCs in various organs and tissues of CX3CR1GFP/+ and CX3CR1GFP/GFP mice, given as total DCs per organ. Results are representative of 2 individual experiments, with 3 to 4 mice per group. ingLN, inguinal LN. (D) Relative CX3CL1 expression in different organs compared with expression levels in the kidneys. Statistical significance was tested with (B) unpaired Student’s t test or (C and D) 1-way ANOVA with Bonferroni multiple-comparison test. **P < 0.01, ***P < 0.001.
To study whether the reduction in DC numbers was unique to the kidney, we compared their abundance in different tissues from CX3CR1GFP/+ and CX3CR1GFP/GFP mice. There was no reduction in liver, lung, heart, bladder, lymph nodes, or spleen (Figure 1C). DCs were less frequent in CX3CR1-deficient mice in the small intestine, but their absolute numbers were more than an order of magnitude lower than in 1 kidney (Figure 1C). The spleens of CX3CR1GFP/GFP mice contained approximately 40% more GFP+ DCs than those of CX3CR1GFP/+ controls (Figure 1C), which might be explained by different homing of DC precursors.
CD11c– GFP+ MPs were substantially reduced in the intestines of CX3CR1-deficient mice (Supplemental Figure 2B), consistent with a recent report (22). There was no reduction of CD11c– GFP+ cells in kidney, liver, lung, heart, bladder, dermis, epidermis, bone marrow, spleen, and brain (Supplemental Figure 2C).
We speculated that the particularly strong CX3CR1 dependence of DCs in the kidney might be due to high expression of its ligand, CX3CL1, in this organ. Indeed, when we determined CX3CL1 by quantitative RT-PCR, its expression in the kidney was much higher than that in other organs except the small intestine (Figure 1D), providing a plausible explanation as to why DCs depended on CX3CR1 only in these organs (Figure 1C). There were no differences in CX3CL1 expression between CX3CR1-deficient and competent mice (Supplemental Figure 2D), ruling out feedback regulation of ligand expression by the receptor.
Dependence of kidney DCs and MPs on CX3CR1 in NTN. To study whether kidney DCs depended on CX3CR1 also under inflammatory conditions, we induced NTN, a widely studied model for crescentic GN. Ten days after disease induction, GFP+ DCs were scarcer in the kidneys of CX3CR1GFP/GFP mice compared with CX3CR1GFP/+ mice (Figure 2A). Of note, there was also a slight, albeit not statistically significant, reduction of renal GFP+ MP numbers at that time point (Figure 2A). The small numbers of CX3CR1+ non-APCs, such as T cells, NK cells, and mast cells, differed very little between CX3CR1GFP/+ and CX3CR1GFP/GFP mice, both under homeostatic conditions and in NTN (Supplemental Figure 1, A and B).
Dependence of kidney DCs and MPs on CX3CR1 in NTN. (A) Absolute numbers of GFP+ DCs and MPs per kidney in CX3CR1GFP/+ and CX3CR1GFP/GFP mice on day 10 after NTN induction. Results are combined from 4 individual experiments. (B) Ly6C expression on GFP+ bone marrow cells from CX3CR1GFP/+ and CX3CR1GFP/GFP mice before transfer into nephritic WT mice. (C) Representative FACS plots of CD11c and MHC-II expression on GFP+ cells recovered from kidneys of nephritic WT mice, which had received 106 GFP+ bone marrow cells from CX3CR1GFP/+ or CX3CR1GFP/GFP mice 96 hours before. (D) Proportion of GFP+ cells among CD45+ cells in the kidneys of nephritic WT mice 48 and 96 hours after transfer of 106 GFP+ bone marrow cells from CX3CR1GFP/+ or CX3CR1GFP/GFP mice. (E) Proportion of GFP+ cells among CD45+ cells in the spleens of nephritic WT mice 96 hours after transfer of 106 GFP+ bone marrow cells from CX3CR1GFP/+ or CX3CR1GFP/GFP mice. Data points represent (A and E) individual mice or (D) organs. Results are representative 2 individual experiments, with 3 to 4 mice per group. Statistical significance was tested with (A) the unpaired Student’s t test or (D) the 2-tailed Mann-Whitney test.
We next asked whether the reduction of kidney DCs in nephritic CX3CR1GFP/GFP mice was only a consequence of the reduced DC numbers under homeostatic conditions (Figure 1B) or whether the recruitment of DC precursors under inflammatory conditions also depended on CX3CR1. We addressed this question by adoptively transferring 106 GFP+ bone marrow cells from CX3CR1GFP/+ and CX3CR1GFP/GFP mice into WT mice 1 day after NTN induction. More than 60% of the GFP+ bone marrow cells expressed Ly6C, which is characteristic of inflammatory monocytes (Figure 2B). Influx of GFP+ cells into the kidneys was analyzed 2 and 4 days after transfer. GFP+ cells expressing the DC markers CD11c and MHC-II were detected in inflamed kidneys (Figure 2C). Importantly, far fewer CX3CR1-deficient cells entered nephritic kidneys at both time points (Figure 2D), whereas more of them were recovered from the spleens (Figure 2E). This indicates that CX3CR1 contributes to entry of DC precursors into the inflamed kidney. In the absence of CX3CR1, these cells relocated to the spleen, similar to our observations in healthy mice (Figure 1C). We did not detect the marker Ly6C on immigrated DCs (data not shown). This may be due to the rapid loss of this marker soon after tissue entry of Ly6C+ monocytes, as recently shown in the lung (38).
CX3CR1 deficiency attenuates NTN. We recently showed that kidney DC maturation stimulates the intrarenal DTH that drives NTN (13). The dearth of DCs in nephritic CX3CR1GFP/GFP mice suggested that DTH should be reduced in these mice. Indeed, flow cytometric analysis of kidney single cell suspensions (gating strategies shown in Supplemental Figure 1, D–F) on day 10 after disease induction revealed reduced numbers of IFN-γ+ CD4+ T cells (Figure 3A) and of TNF-producing DCs and MPs in CX3CR1-deficient mice (Figure 3B), suggesting an attenuated intrarenal DTH response. IL-17+ CD4+ T cells were only slightly and not significantly reduced (Supplemental Figure 3B), consistent with the recent finding that Th17 cells are more important in the early disease phase (14). Other early immune mediators were also not affected by CX3CR1 deficiency, as evidenced by unchanged IFN-γ, TNF, CXCL10, and CXCL16 expression in CX3CR1GFP/+ and CX3CR1GFP/GFP mice after 24 hours (Supplemental Figure 3A).
CX3CR1 deficiency reduces intrarenal Th1 response and improves kidney function. (A) Absolute numbers of IFN-γ–producing CD4+ T cells and (B) of TNF-producing DCs and MPs per kidney of CX3CR1GFP/+ reporter mice and CX3CR1GFP/GFP-deficient mice 10 days after NTN induction, as determined by intracellular flow cytometry. In A, cell numbers in 4 individual experiments were given as percentage of the mean cell number in the CX3CR1-competent groups. (C) Creatinine clearance in CX3CR1GFP/+ and CX3CR1GFP/GFP mice 10 days after NTN induction. (D) Blood urea nitrogen in CX3CR1+/+ and CX3CR1GFP/GFP mice 10 days after NTN induction. (E) Albumin excretion normalized to creatinine by CX3CR1GFP/+ and CX3CR1GFP/GFP mice 10 days after NTN induction. Urine was collected for 12 hours. Data points represent individual mice, and results (A–C) are combined from 2 to 4 individual experiments, with 2 to 5 mice per group, or (D and E) are representative of 2 individual experiments, with 10 mice per group. Statistical significance was tested with the 2-tailed Mann-Whitney test.
Functional parameters like creatinine clearance, blood urea nitrogen, and proteinuria were improved in CX3CR1GFP/GFP mice (Figure 3, C–E), and histological examination of kidney sections revealed fewer tubular casts and crescents in CX3CR1GFP/GFP mice on day 10 (Supplemental Figure 3C), indicating that the loss of CX3CR1 attenuates NTN. On day 15, the histological features of kidney damage were even more pronounced (Figure 4, A–C). CX3CR1GFP/GFP mice also featured fewer periglomerular F4/80+ cells (Figure 4, D and E), indicating a reduction in DCs and/or MPs. Despite their reduced numbers (Figure 2A), kidney DCs of CX3CR1GFP/GFP mice still formed periglomerular infiltrates (6) in NTN (Figure 4F), indicating that CX3CR1 was dispensable for intrarenal APC migration toward inflamed glomeruli.
CX3CR1 deficiency attenuates NTN. (A) Kidney sections of CX3CR1+/+ and CX3CR1GFP/GFP animals 15 days after NTS challenge (Masson trichrome; original magnification, ×200). (B) Percentage of crescentic glomeruli in histological sections of CX3CR1+/+ and CX3CR1GFP/GFP mice on day 15 after disease induction. (C) Tubular casts per high-power field (hpf) (original magnification, ×100) in CX3CR1+/+ and CX3CR1GFP/GFP mice 15 days after NTS challenge. (D) Representative microphotographs of immunostained F4/80+ cells in kidney cortices from CX3CR1+/+ and CX3CR1GFP/GFP mice on day 15 after NTN induction (original magnification, ×200). (E) Quantification of infiltrating F4/80+ cells in CX3CR1+/+ and CX3CR1GFP/GFP animals 15 days after NTS challenge. (F) Immunofluorescence microscopy of kidney sections from nephritic CX3CR1GFP/+ and CX3CR1GFP/GFP mice on day 10 after NTN induction (red [autofluorescence], green [GFP]). Scale bar: 50 μm. Data points represent individual mice, and (D–F) results are representative of 2 individual experiments, with 12 to 16 mice per group. Statistical significance was tested by 2-tailed Mann-Whitney test.
Cell-intrinsic DC functions are independent of CX3CR1 expression. To understand how CX3CR1 deficiency attenuated intrarenal DTH and nephritis symptoms, we asked whether DCs were functionally defective in the absence of this receptor. We first examined the systemic Th1 response against sheep Ig, which is induced by DCs in lymphatic tissues after injection of the nephrotoxic sheep serum (39). This response was unaltered, as evidenced by similar subcutaneous DTH response against sheep Ig (Figure 5A) and by similar production of the Th1 and Th17 cytokines, IFN-γ, TNF, and IL-17, by splenocytes (Figure 5B). These findings excluded the possibility that the attenuated intrarenal DTH response in CX3CR1GFP/GFP mice resulted from a failure to activate a nephritogenic T cell response.
Cell-intrinsic DC functions are unaltered by CX3CR1 deficiency. (A) DTH reaction in the skin of CX3CR1GFP/+ reporter mice and CX3CR1GFP/GFP-deficient mice, rechallenged by footpad injection with NTS. Depicted is footpad swelling in comparison with the contralateral footpad injected with vehicle control. (B) IFN-γ, IL-17, and TNF concentration in the supernatant of 24-hour splenocyte culture from nephritic CX3CR1GFP/+ and CX3CR1GFP/GFP mice rechallenged with NTS. 107 total splenocytes were cultured for 24 hours in 1 ml medium and 1:200 NTS. (C) MFI of CD86 and MHC-II expression on kidney DCs from CX3CR1GFP/+ mice and CX3CR1GFP/GFP mice, determined by flow cytometry. (D) Representative FACS plots of the in vivo uptake of fluorescently labeled OVA by kidney DCs of nephritic CX3CR1GFP/+ and CX3CR1GFP/GFP mice gated on CD45+MHC-II+CD11c+ cells. Numbers show percentages of OVA+ DCs. (E) Representative histograms of T cell proliferation and CFSE dilution and division indices (DI) in a coculture of OVA-specific T cells and kidney DCs from nephritic CX3CR1GFP/+ and CX3CR1GFP/GFP mice injected with 1 mg OVA 1 hour prior to cull. (F) IFN-γ and IL-17 concentrations in supernatants of 72-hour cocultures from E. Data points represent individual mice, and results are representative of 2 to 4 experiments, with 3 to 4 mice per group. Statistical significance was tested with the unpaired Student’s t test.
We therefore focused on intrarenal DCs. CX3CR1-deficient and -competent kidney DCs from nephritic mice expressed equal levels of costimulatory molecules and MHC-II (Figure 5C). Next, we studied their ability to capture antigen by injecting the model antigen, OVA, a 45-kDa protein that can constitutively pass the glomerular filter (40). Regardless of CX3CR1 expression, DCs took up similar amounts of OVA (Figure 5D). To examine the principal DC function, the activation of naive T cells, we injected CX3CR1-deficient and CX3CR1-competent nephritic mice with OVA and cocultured kidney DCs with OVA-specific Th cells (OT-II cells). CX3CR1GFP/+ and CX3CR1GFP/GFP DCs elicited similar proliferation profiles and cytokine production by OT-II cells (Figure 5, E and F). Therefore, the observed differences in disease severity were not due to DC-intrinsic functional defects, supporting their reduced numbers as an underlying reason.
DCs in the renal cortex are especially dependent on CX3CR1. When we reexamined kidney sections of healthy CX3CR1GFP/+ and CX3CR1GFP/GFP mice by immunofluorescence microscopy, the paucity of GFP+ cells in the latter mice seemed to preferentially affect the kidney cortex (Figure 6A). To verify this histological impression in a quantitative manner and to distinguish between DCs and MPs, we surgically separated the renal medulla from the cortex, produced single cell suspensions by separate collagen digestion, and analyzed these by flow cytometry. The cortex of CX3CR1GFP/+ mice contained 3 times more GFP+ cells than the medulla, and 80% of them expressed the DC marker CD11c, whereas less than 40% of GFP+ cells in the medulla did so (Figure 6, B and C). Consequently, the absolute numbers of GFP+ DCs were about 6 times higher in the cortex than in the medulla (Figure 6D). In CX3CR1GFP/GFP mice, DC numbers were reduced 9 fold from 200 × 103 to 22 × 103 cells per kidney cortex, whereas medullary DCs were reduced 3.5 fold from 38 × 103 to 11 × 103 cells per kidney (Figure 6D). MP numbers were increased 2.5 fold in the cortices of CX3CR1GFP/GFP mice (Figure 6E). Of note, the mice used in this experiment were younger than those used in the other experiments (Figure 1 and Figure 6, G and H), explaining the relatively low absolute DC numbers. Nevertheless, DC numbers were similarly reduced, indicating that the kidney DC deficiency in CX3CR1-deficient mice was age independent.
DCs in the renal cortex particularly depend on CX3CR1. (A) Histological quantification of GFP+ cells in cortical and medullary kidney sections of healthy CX3CR1GFP/+ reporter mice and CX3CR1GFP/GFP-deficient mice. Each data point represents 1 high-power field (original magnification, ×200). Statistical significance was calculated by Mann Whitney test. (B) Absolute numbers of GFP+ cells in the cortices and medullas of 1 kidney of healthy CX3CR1GFP/+ mice (gray bars) and CX3CR1GFP/GFP mice (black bars), determined by flow cytometry. (C) Representative FACS plots of CD45+GFP+ cells in kidney cortices and medullas of CX3CR1GFP/+ mice. (D and E) Absolute numbers of (D) DCs and (E) MPs in the renal cortices and medullas of healthy CX3CR1GFP/+ mice (gray bars) and CX3CR1GFP/GFP mice (black bars). (F and G) Absolute numbers of (F) DCs and (G) MPs in the cortices and the medullas of 1 kidney of nephritic CX3CR1GFP/+ mice (gray bars) and CX3CR1GFP/GFP mice (black bars) on day 10 after NTN induction. Results are representative of 2 to 3 individual experiments, with 3 to 4 mice per group. Statistical analysis was performed using 1-way ANOVA with Bonferroni multiple-comparison. **P < 0.01, ***P < 0.001.
The kidney cortices of nephritic CX3CR1GFP/+ mice contained 416 × 103 GFP+ DCs, compared with 164 × 103 DCs in CX3CR1GFP/GFP mice (60% reduction), whereas only 96 × 103 DCs were seen in the medullas of CX3CR1-competent mice and 44 × 103 DCs were seen in those of CX3CR1-deficient mice (55% reduction) (Figure 6F). Thus, even though proportional DC reduction was similar, the absolute deficit of kidney DCs in nephritis was more prominent in the cortex (–252 × 103 DCs) than in the medulla (–52 × 103 DCs). Furthermore, there were approximately 32 × 103 fewer MPs in the cortices and approximately 20 × 103 fewer medullary MPs in CX3CR1-deficient nephritic mice (Figure 6G). Taken together, our findings demonstrated that, under homeostatic conditions, CX3CR1 primarily affected DCs in the cortex, and, in the condition of nephritis, affected both cortical and medullary DCs and to a lesser extend also MPs.
Cortical, but not medullary, DCs can stimulate Th cells in GN. We reasoned that the proximity of cortical DCs to the glomeruli might render these cells particularly relevant in GN. When we compared the phenotype of medullary and cortical APCs in healthy mice, we observed similar expression of CD11b, F4/80, and CX3CR1 and higher CD11c expression on cortical CX3CR1+ cells (Figure 7A). For the most part, cortical and medullary DCs expressed similar levels of MHC-II and of the costimulatory molecules CD80, CD86, and CD40 under homeostatic conditions (Figure 7B), notwithstanding some variability of expression levels between experiments. In nephritic mice, expression of CD40 and MHC-II on cortical DCs slightly exceeded that on medullary DCs in 3 out of 5 experiments, consistent with higher maturation of the former (Figure 7B).
Cortical, but not medullary, DCs can stimulate Th cells in GN. (A) Flow cytometric analysis of CX3CR1+ APCs from kidney cortices (gray lines) and medullas (black dashed lines) of CX3CR1GFP/+ reporter mice for expression levels of CD11c, CD11b, F4/80, CX3CR1, and CD103. (B) MFI, reflecting expression levels of MHC-II, CD40, CD86, and CD80 on cortical (white bars) and medullary (black bars) DCs in healthy mice (day 0) or mice on day 7 or 10 after NTN induction. (C) Representative CFSE dilution profiles, reflecting T cell proliferation in a 72-hour coculture of OVA-specific CD4+ T cells and OVA-loaded cortical, medullary, or splenic DCs derived from healthy (gray solid) or 7-day nephritic (black line) WT mice. 2 × 104 DCs were loaded with 1 mg/ml OVA for 2 hours, washed, and cocultured with 1.5 × 105 OT-II cells for 72 hours. (D) Division indices of OT-II cells in coculture from C. (E) IFN-γ and IL-17 concentrations in 200 μl medium after 72 hours coculture, as in C. Results are representative of at least 2 individual experiments, with at least 3 mice per group. Statistical significance was analyzed applying the paired Student’s t test. **P < 0.01.
NTN is driven by a Th cell–dependent intrarenal DTH (11). Therefore, we cocultured cortical and medullary DCs with the model antigen, OVA, and OT-II cells. OVA-loaded cortical and medullary DCs from healthy mice caused little T cell proliferation compared with control splenic DCs (Figure 7C). By contrast, OVA-loaded DCs from the cortices of nephritic mice induced strong OT-II cell proliferation (Figure 7, C and D) and secretion of IFN-γ and IL-17 (Figure 7E). Remarkably, medullary DCs from nephritic kidneys still only elicited minimal OT-II cell proliferation and cytokine production (Figure 7, C–E). These results suggested that Th cell stimulation during NTN depends mainly on cortical DCs, implying that only these DCs drive NTN progression.
Medullary DCs poorly process antigen for MHC-II presentation. To understand why medullary DCs poorly stimulated Th cells, we first examined their survival in vitro. A similar fraction of cortical and medullary DCs survived a culture period of 24 hours (cortical DCs: 55.4% ± 0.7% survival; medullary DCs: 58.5% ± 2.4% survival), excluding selective death as underlying reason. DC maturation parameters differed little (Figure 7B). We therefore speculated about distinct antigen handling as an underlying reason and first asked whether medullary DCs were unable to endocytose antigen. However, medullary DCs captured slightly more fluorescent OVA than cortical DCs in an in vitro culture both under homeostatic conditions (Figure 8, A and B) and in NTN (Figure 8B). To test whether medullary DCs might not have antigen access in vivo, we injected fluorescent OVA i.v. into mice and determined its uptake by medullary and cortical DCs. More medullary than cortical DCs captured OVA under homeostatic conditions, and they also took up more filtered antigen per cell (Figure 8, C–E). On day 10 of nephritis, when the mice are heavily proteinuric, the proportion of antigen-containing cortical DCs was as high as that in medullary DCs (Figure 8, C–E). However, the antigen uptake per cell was 3-fold higher in medullary DCs than in cortical DCs (Figure 8, D and E). These findings exclude the possibility that impaired antigen uptake explains the functional defect of medullary DCs.
Medullary DCs do not process antigen for MHC-II presentation. (A) Uptake of fluorescently labeled OVA by sorted CX3CR1+ APCs from kidney cortices (white squares) and medullas (black squares) of healthy CX3CR1GFP/+ reporter mice. Sorted GFP+ cells were incubated with OVA for 20 minutes at 37°C, washed, and analyzed by flow cytometry. (B) Sorted cortical (white bars) and medullary (black bars) DCs from healthy or 10-day nephritic mice were incubated with 10 μg/ml OVA, as in A. MFI of OVA+ cells, reflecting average amount of antigen uptake per cell. (C) Percentage of OVA+ DCs in cortex (white bars) and medulla (black bars) 30 minutes after i.v. injection of fluorescently labeled OVA into healthy or 10-day nephritic mice. (D) Representative FACS plots of the in vivo OVA uptake of cortical and medullary CD45+MHC-II+ cells in healthy or 10-day nephritic mice, 30 minutes after i.v. injection of Alexa Fluor 647–conjugated OVA. (E) MFI of OVA+ cells in cortex and medulla 30 minutes upon i.v. injection of OVA, as in C. (F) MFI of cortical and medullary DCs, indicating cleaved DQ-OVA after 20 minutes of incubation with 200 μg/ml DQ-OVA. (G) Analysis of cleaved DQ-OVA per endocytosed Alexa Fluor 647–conjugated OVA in cortical and medullary DCs, after 3 hours of incubation with 25 μg/ml DQ-OVA and Alexa Fluor 647–conjugated OVA. (H) mRNA for Cathepsin H, invariant chain, and H2-DM in cortical and medullary DCs from 7-day nephritic mice, relative to GAPDH expression. Results represent 2–3 experiments, with 3 to 5 mice per group. Statistical analysis (B–E) by 1-way ANOVA with Bonferroni test or (F and H) by paired Student’s t test. *P < 0.05, **P < 0.01, ***P < 0.001.
We next speculated that medullary DCs might function like MPs, which capture more antigen than DCs but degrade it before it can be presented to T cells (41). To test this, we offered the DCs DQ-OVA, which becomes fluorescent once it is cleaved. Medullary DCs cleaved somewhat more DQ-OVA than cortical DCs (Figure 8F), but this increase correlated with their higher endocytotic activity (Figure 8G). Thus, medullary DCs did not possess the high degradative activity of MPs. This left the explanation that the antigen processing and MHC-II loading machinery is defective in medullary DCs. While the antigen-degrading enzyme cathepsin H was not differentially expressed, there was indeed less expression of invariant chain and H2-DM in medullary DCs, suggesting that medullary DCs are less well equipped to load processed antigen onto MHC-II for presentation to Th cells (Figure 8H).
Medullary DCs regulate innate immunity in the kidney. The inability of medullary DCs to activate Th cells raised the question of what physiological role these cells might play. We reasoned that their location might be particularly suitable for the sentinel function we recently described for kidney DCs in PN (4), because uropathogenic E. coli ascend through the collecting ducts in the medulla. To test this hypothesis, we determined DC production of the chemokine CXCL2, which attracts neutrophils into the infected kidney. Indeed, 3 hours after infection, medullary DCs produced far more CXCL2 than cortical DCs (Figure 9, A–C). MPs, identified by lack of CD11c expression, produced very little CXCL2 (Figure 9A).
Medullary DCs regulate the innate immunity against PN. (A) Representative FACS plots of CXCL2 production by CD45+MHC-II+ cells in kidney cortex and medulla 3 hours after second UPEC instillation. Cells were incubated with brefeldin A for 4 hours at 37°C prior to staining. (B) Percentage of CXCL2-producing cells of CD45+MHC-II+CD11c+ cells in cortex (white squares) and medulla (black squares). (C) MFI for CXCL2 of cortical and medullary CXCL2+ DCs, representing CXCL2 production per cell. (D) CFUs per kidney in CX3CR1GFP/+ reporter mice and CX3CR1GFP/GFP-deficient mice 6 hours after second UPEC instillation. (E) Numbers of neutrophils (PMNs) per kidney in CX3CR1GFP/+ and CX3CR1GFP/GFP mice 6 hours after second UPEC instillation. (F) Representative histogram of CXCL2 staining (black line) of CD45+Ly6G+ neutrophils from CX3CR1GFP/+ and CX3CR1GFP/GFP mice 6 hours after second UPEC instillation, compared with isotype control (gray solid). Cells were incubated with brefeldin A for 4 hours at 37°C prior to staining. Data points represent individual mice; and results are representative of 2 to 3 individual experiments, with 6 mice per group. Statistical significance was analyzed by (B and C) Wilcoxon signed-rank test or (D and E) 2-tailed Mann-Whitney nonparametric test.
We next induced PN in CX3CR1-deficient mice that possess fewer kidney DCs (Figure 1B and Figure 6D) in order to determine consequences for the anti-infectious immune response. Neutrophil numbers in CX3CR1-deficient mice were somewhat reduced at 3 hours after infection (CX3CR1+/+ mice: 81 × 103 ± 17 × 103 neutrophils per kidney; CX3CR1GFP/GFP mice: 54 × 103 ± 17 × 103 neutrophils per kidney; P < 0.01), indicating an initial delay of neutrophil recruitment. However, at 6 hours after infection, bacterial CFUs (Figure 9D) and neutrophil numbers (Figure 9E) did not differ between CX3CR1-deficient and -competent mice. This was not because the fewer DCs in CX3CR1-deficient mice produced more CXCL2 per cell (CX3CR1GFP/+ mice: MFICXCL2 = 7,957 ± 774; CX3CR1GFP/GFP mice: MFICXCL2 = 7,948 ± 487). Instead, we found that neutrophils commenced robust CXCL2 production at 6 hours after infection (Figure 9F). This suggested that the medullary DCs in CX3CR1-deficient mice were sufficient for initiating neutrophil recruitment, and once neutrophils were present in the infected kidney, they produced large amounts of CXCL2. This production compensated for the DC deficiency in the absence of CX3CR1 with respect to antibacterial immune defense.
CX3CR1 is widely used to identify APCs in various tissues, but few functional roles have been described. Here we report that CX3CR1 strongly affects the abundance of DCs, but not of MPs, in the kidney. The small intestine was the only other organ demonstrating APC dependence on CX3CR1 under homeostatic conditions, albeit primarily affecting MPs. The kidney and the intestine expressed the highest levels of CX3CL1 of all organs tested, providing a plausible explanation for the CX3CR1 dependency of kidney DCs. This identifies CX3CR1 as a chemokine receptor that targets kidney DCs with relative specificity. To our knowledge, this is the first example of an organ-specific chemokine receptor that affects DCs rather than lymphocytes.
The CX3CR1 dependence of kidney DCs in the steady state may theoretically result from an effect on precursor recruitment, their differentiation into DCs, or on DC survival/retention in the kidney. The slow turnover of kidney DCs in the steady state (42) hinders discriminating among these possibilities. Under inflammatory conditions, recruitment of DC precursors to the kidney partially depended on this CX3CR1. This is consistent with previous studies showing CX3CR1-dependent monocyte recruitment and/or survival to inflamed vessels and liver (29–31). CX3CR1+ monocytes can give rise to both DCs and MPs (5, 33). However, we have not formally shown that monocytes were the precursors of DCs in NTN. This may be doable by using CCR2-deficient mice, in which inflammatory monocytes cannot leave the bone marrow (43). Furthermore, it remained unclear why CX3CR1 selectively affected DCs, but not MPs, in homeostasis, although both cell types express this receptor. Further studies may clarify the exact ontogeny of kidney DCs in homeostasis and inflammation (44, 45).
Kidney DC numbers were reduced also in nephritic CX3CR1-deficient mice. Consequently, intrarenal DC-dependent inflammation and the course of crescentic GN were markedly attenuated in CX3CR1-deficient mice. This confirmed our previous study, in which we observed NTN attenuation after depleting kidney DCs with the use of CD11c-DTR mice (13). However, in that study, we unavoidably depleted DCs also in other tissues, which may be functionally relevant. Furthermore, CD11c-DTR mice are hampered by a side effect, bone marrow release of neutrophils and monocytes after DC depletion, which can impact immune responses, especially in PN (46). Our present findings allow conclusions regarding kidney DCs in the absence of these shortcomings. Furthermore, they suggest that targeting CX3CR1 might be useful for treating GN, especially since not only DCs, but also MPs (the DTH effector cells), were to some extent CX3CR1 dependent in kidney inflammation.
The particularly strong CX3CR1 dependence of cortical DCs and their intrarenal location suggested that NTN is primarily driven by these DCs. Indeed, only cortical DCs were able to activate Th cells. This activation is important in NTN, because it induces chemokines and cytokines that assemble and maintain the tubulointerstitial infiltrates that drive disease progression (2, 11, 13). Mechanistic analysis revealed that the inability of medullary DCs to activate T cells did neither result from their failure to mature, nor from defective antigen uptake. On the contrary, medullary DCs were superior at endocytosis, despite being “downstream” of the nephron from cortical DCs and thus further away from antigen filtered under proteinuric conditions. Instead, our findings support the interpretation that only cortical DCs processed the antigen they captured in a manner suitable to stimulate Th cells. These findings demonstrate that cortical and medullary DC functions differ.
The inability of medullary DCs to perform the hallmark DC function, activating T cells, raised the question of whether these cells can still be considered DCs. Some recent studies on intestinal APCs proposed that CD11c+CX3CR1+ cells should be generally considered MPs and that only CD103+CD11c+ phagocytes represent DCs (22, 47, 48), but this is not generally accepted (49). In contrast to the intestine, almost all DCs in the kidney are CX3CR1+CD11c+, whereas CD103+ DCs are a minority of less than 5% (50). We had previously classified CD11c+ kidney APCs as DCs, because they resembled splenic DCs in their ability to activate T cells (6). Also their transcriptome is closer to that of tissue DCs than that of MPs (7). These findings did not exclude that only a subset of kidney CD11c+ cells was capable of T cell activation, and here we show that only cortical CD11c+ cells did so, at least in NTN. We speculated that medullary CD11c+ cells might functionally resemble MPs, given that they captured large amounts of antigen in vivo. However, this was most likely due to the concentration of filtered antigen in the kidney medulla, which exposed cells in this compartment to higher antigen quantities. The in vitro antigen uptake of medullary DCs was only somewhat higher than that of cortical DCs. Moreover, medullary DCs did not degrade antigen too swiftly for antigen presentation, which has been stated to be characteristic of MPs (41). Instead, we found that medullary DCs were specialized at sentineling against PN. For this purpose, these DCs are strategically positioned adjacent to the collecting ducts through which UPECs first pass when they invade the kidney. In response to infection, medullary DCs rapidly produced neutrophil-attracting chemokines like CXCL2. Cortical DCs produced fewer chemokines, and MPs produced none, at least at the early time points that we examined. This sentinel function appears more compatible with the regulatory role of DCs, rather than with the immune effector functions of MPs. However, there is far more plasticity between these cell types than previously thought, especially in the kidney (51). Final classification of these APCs requires more discussion and a general consensus. For clarity, we will continue to refer to medullary CD11c+ APCs as DCs.
The defense against PN was barely impaired in CX3CR1-deficient mice, whereas DC depletion with the use of CD11c-DTR mice had delayed this defense (4). These transgenic mice usually achieve higher kidney DC depletion rates than those observed for medullary DCs in CX3CR1-deficient mice. The remaining medullary DCs apparently sufficed to initiate neutrophil recruitment. This recruitment was somewhat less efficient, but once the first neutrophils had entered, they produced CXCL2 themselves and the bacteria were cleared with little delay. This can only operate in infections, in which delayed immune cell recruitment aggravates disease, but not in immune-mediated diseases, in which such a delay would be protective. Compensatory chemokine production by neutrophils, together with the minor effect of CX3CR1 on medullary DCs, can explain why the lack of this receptor only marginally affected PN.
In conclusion, we have shown that cortical and medullary DCs are specialized at regulating adaptive and innate immune responses in NTN and PN, respectively. The abundance of cortical, and to a lesser extent of medullary DCs, depended on CX3CR1 expression. The relative kidney specificity of this receptor recommends it as a potential therapeutic target in immune-mediated kidney diseases, especially as the susceptibility to bacterial infections was not markedly increased. Thus, targeting CX3CR1, for example, by systemic injection of blocking antibodies or recombinant CX3CL1 (21, 37), might represent a promising treatment for GN with fewer side effects than general immunosuppressive therapies. Future studies are required to assess the benefit of CX3CR1-mediated DC targeting in the kidney compared with potential side effects resulting from the loss of other CX3CR1 functions.
Animals. C57/BL6 mice, CX3CR1GFP/+ reporter mice, and CX3CR1GFP/GFP-deficient mice were bred and kept in specific pathogen–free conditions at the animal facility of the University of Bonn. All lines had been backcrossed more than 10 times onto the C57BL/6 background.
Isolation of murine kidney DCs and OT-II cells. Complete kidneys or cortex and medulla preparations were digested with collagenase (Roche Diagnostic) and DNAse-I, as previously described (6). Tubular fragments from digested kidneys were removed by filtration. CD11c+ DCs were then enriched using nanobead-labeled CD11c-specific monoclonal antibodies (clone N418) (Miltenyi). Magnetic bead separation was carried out according to manufacturer’s instructions. Purity was typically 90%–95% of CD45+ cells. OT-II cells were isolated from spleens and lymph nodes of OT-II mice and enriched using a commercially available CD4+ T Cell Isolation Kit (Miltenyi). Purity was usually about 85% of CD45+ cells.
Flow cytometry. After treatment with Fc-blocking antibodies (clone 2.4G2), cells were stained for 15 minutes on ice with fluorochrome-labeled monoclonal antibodies against CD11c (clone HL3), I-Ab (AF6-120.1), and CD40 (3/23) (BD Biosciences) as well as CD45 (30-F11), CD11b (M1/70), Gr1 (RB6-8C5), CD4 (GK1.5), CD3 (145-2C11), CD86 (GL1), CD80 (16-10A1), and CD103 (2E7) (eBioscience). For intracellular cytokine staining, single cell suspensions were incubated in RPMI (10% FCS) with 1 μl/ml GolgiPlug and 1 μl/ml GolgiStop (BD Biosciences) for 4 hours at 37°C. T cells were restimulated with PMA/ionomycin for 4.5 hours, starting 30 minutes before addition of GolgiPlug and GolgiStop. After cell surface staining, cells were fixated in 4% formalin (Morphisto GmbH) for 10 minutes on ice. Cell membranes were permeabilized with PermWash (BD Biosciences) for 15 minutes at room temperature. Intracellular staining was performed in PermWash for 20 minutes at room temperature using flourochrome-labeled monoclonal antibodies against TNF-α (clone MP6-XT22), IFN-γ (XMG1.2), and IL-17 (9D3.1C8). Cells were analyzed with a BDCantoII (Becton Dickinson).
T cell activation assays. Either mice were injected with 1 mg OVA 1 hour prior to harvesting kidneys or isolated cortical and medullary DCs were loaded in vitro for 2 hours with 1 mg/ml OVA. DCs were cocultured with OT-II cells in 200 μl RPMI (10% FCS) in 96-well plates for 72 hours. T cell proliferation was measured by CFSE dilution. Therefore, isolated T cells were stained with 1 nM CFSE in PBS for 10 minutes at 37°C and washed twice with ice-cold RPMI (10% FCS). Cytokine induction was analyzed by intracellular staining of OT-II cells for IFN-γ and IL-17. Cytokines in the supernatants were measured using the Th1/Th2 10plex FlowCytomix Multiplex Kit (Bender MedSystems).
Endocytosis and cleavage assays. For comparing the uptake of filterable antigen by cortical and medullary DCs in vivo, mice were injected with 500 ng Alexa Fluor 647–conjugated OVA (Invitrogen) per g body weight. Single cell suspensions were obtained from kidney cortices and medullas 30 minutes after antigen injection. Cells were stained and analyzed via flow cytometry. For in vitro uptake studies, cortical and medullary DCs were sorted with a FACSDiva (Becton Dickinson). Cells were then incubated with indicated OVA concentrations for 30 minutes at 37°C, washed, and analyzed by flow cytometry. For comparing the antigen cleavage, DQ-OVA (Invitrogen), which becomes fluorescent upon cleavage, was used in addition to Alexa Fluor 647–conjugated OVA, which served as a control for antigen uptake.
RNA preparation and RT-PCR. RNA from FACS-sorted cortical and medullary DCs was extracted using TRIzol (Invitrogen) and Chlorophorm (Carl Roth) according to standard laboratory methods. Whole tissue RNA was extracted using the RNA NucleoSpin Kit (Macherey-Nagel) according to manufacturer’s instructions. RNA was reverse transcribed into cDNA using the High-Capacity Reverse Transcription Kit (Applied Biosystems). Quantitative PCR was performed for 40 cycles using SYBR Green (Applied Biosystems). The following primer sequences were used: invariant chain (forward) 5′-AGGCTCCACCTAAAGAGCCACTG-3′, (reverse) 5′-ACAGACACCAGTCTCAAGCCCC-3′; H2-DM (forward) 5′-ACGTGCGTGCTGAATGATGCT-3′, (reverse) 5′-AGCCCGTTTTGCAAGCGATGAATA-3′; cathepsin H (forward) 5′-AACATGTGTGGCCTGGCTGC-3′, (reverse) 5′-TGATGTCACGTGGGTGGGCT-3′; and CX3CL1 (forward) 5′-GCCGCGTTCTTCCATTTG-3′, (reverse) 5′-CGCACATGATTTCGCATTTC-3′. All samples were run in triplicate and normalized to GAPDH or 18s rRNA.
Induction of NTN and functional studies. Nephrotoxic serum nephritis was induced in 8- to 12-week-old age- and sex-matched CX3CR1 reporter, CX3CR1-deficient, and WT mice by i.v. injection of a cumulative dose of 13 μl per g bodyweight on 3 consecutive days or by i.p. injection of 0.5 ml NTN serum per mouse, as previously described (13, 52). On day 4 and 9, urine was collected in metabolic cages for 12 hours. Mice were culled on day 10 or on day 15. Flow cytometrical analysis and analysis of creatinine clearance were performed on day 10 after disease induction. Histological analysis was performed on day 15. Serum was derived from whole blood after cardiac puncture. Urinary creatinine and serum creatinine were measured using standard laboratory methods in the Central Laboratory of the University Hospital of Bonn. Creatinine clearance was calculated by the formula CCr = (UCr × VolU)/(SCr × t), where CCr stands for creatinine clearance, UCr stands for creatinine concentration in urine, VolU stands for urine volume (in ml), SCr stands for creatinine concentration in serum, and t stands for time in metabolic cage (in minutes).
Transfer experiments. Total bone marrow cells were obtained from the femurs of CX3CR1 reporter and CX3CR1-deficient mice. 107 bone marrow cells, of which approximately 10% expressed GFP, were transferred into WT mice, which had been injected with nephrotoxic sheep serum (NTS) 1 day before. Single cell suspensions were obtained after 48 or 96 hours from kidneys and spleens. Proportions of GFP+ cells among CD45+ cells and phenotype of these cells were determined by flow cytometry.
Histology. Fluorescence microscopy was performed on 3-μm paraffin sections in PFA-fixed kidneys derived from healthy and 10-day nephritic CX3CR1GFP/+ reporter mice and CX3CR1GFP/GFP-deficient mice. GFP+ cells were quantified using CellF software (Olympus). Light microscopy was performed on 3-μm paraffin sections of PFA-fixed tissue derived from 15-day nephritic mice, stained by Masson’s trichrome coloration using standard protocols. Kidney damage was histologically scored by an observer blinded to the identity of samples. For determining the proportion of crescentic glomeruli, at least 80 glomeruli per section were examined. F4/80+ cells were stained using rabbit antibody to F4/80 (MCA497B, Serotec) diluted 1:50. F4/80+ cell infiltration was then quantified using ImageJ software (NIH).
Urinary tract infection model. Uropathogenic E. coli strain 536 (UPEC) (53) were grown for 5 hours at 37 °C in LB medium. Bacteria were harvested by centrifugation at 1,200 g for 10 minutes and resuspended in 2 ml LB medium to a final concentration of 1 × 1010 CFUs per ml. Female mice of 8 to 12 weeks of age were anesthetized with Avertin (40 mg 2,2,2-tri bromoethanol, Sigma-Aldrich) dissolved in 1 ml tert-amyl alcohol (0.01 ml g–1 body weight i.p.) and were infected by transurethral instillation of 1 × 109 UPEC using a flexible polyethylene catheter (outer diameter 0.6 mm; BD) coated with Instillagel (Farco Pharma). Three hours later the procedure was repeated to induce PN. Before analysis, mice were perfused with sterile PBS. The number of ascended bacteria was quantified by scoring CFUs after overnight culture of kidney collagenase digest or by homogenization in PBS with an Ultra Turrax at 37°C on CPS ID plates (Biomerieux), as described previously.
Statistics. Results are expressed as mean ± SEM. Comparisons were drawn using a 2-tailed paired Student’s t test or the nonparametric Wilcoxon signed-rank test (cortex and medulla from 1 mouse) or unpaired Student’s t test, 1-way ANOVA in combination with Bonferroni multiple-comparison test, or the 2-sided nonparametric Mann Whitney U test (comparison between individual mice) (Prism 4, Graphpad Software). P values of less than 0.05 were considered significant.
Study approval. All animal studies have been approved by The Landesamt für Natur, Umwelt und Verbraucherschutz Nordrhein Westfalen, Recklinghausen, Germany.
The authors thank Steffen Jung for CX3CR1-knockin mice; Anke Carstensen for the analysis of mouse serum and urine; Anett Peters, Chrystel Llanto, and Jessica Gonyer for technical assistance; and Bart Lambrecht and Natalio Garbi for helpful suggestions. We acknowledge support by the Central Animal Facilities and the Flow Cytometry Core Facility of the Medical Faculty of Bonn University. K. Hochheiser is supported by a fellowship of the German National Academic Foundation (Studienstiftung des Deutschen Volkes). This work was supported by the Deutsche Forschungsgemeinschaft (KFO228, SFB704, SFBTR57, Leibniz award to C. Kurts). P.A. Knolle and C. Kurts are members of the Excellence Cluster “Immunosensation.”
Address correspondence to: Katharina Hochheiser, Institutes of Molecular Medicine and Experimental Immunology (IMMEI), Friedrich-Wilhelms-Universität, 53105 Bonn, Germany. Phone: 49.228.287.11033; Fax: 49.228.287.11052; E-mail: khochhei@uni-bonn.de. Or to: Christian Kurts, Institutes of Molecular Medicine and Experimental Immunology (IMMEI), Friedrich-Wilhelms-Universität, 53105 Bonn, Germany. Phone: 49.228.287.11050; Fax: 49.228.287.11052; E-mail: ckurts@web.de.
Conflict of interest: The authors have declared that no conflict of interest exists.
Reference information: J Clin Invest. 2013;123(10):4242–4254. doi:10.1172/JCI70143.